01 — At a Glance
The Generic Oncology Machine That Just Lost Its Lead Molecule
- 52-Week High / Low₹1,060 / ₹660
- Q3 FY26 Revenue₹705 Cr
- Q3 FY26 PAT₹151 Cr
- Q3 FY26 EPS (₹)₹8.46
- Annualised EPS (Q3×4)₹33.84
- Book Value₹483
- Price to Book2.11x
- Dividend Yield0.58%
- Debt / Equity0.03x
- Interim Dividend₹1.50/share
The Plot Twist: Natco just delivered revenue of ₹705 crore (+8.3% YoY), PAT of ₹151 crore, and declared an interim dividend of ₹1.50 per share. Sounds normal. Except — Revlimid, which was printing ₹150+ crore profit in FY25, contributed literally zero rupees to Q3 earnings. The patent expired in Q2. Yet the stock is up 32% in one year. Markets are celebrating the death of their profit engine because management is making bigger bets elsewhere. Welcome to India’s weirdest pharma story.
02 — Introduction
From Revlimid to Semaglutide: The Grand Pivot
Natco Pharma is a vertically integrated, R&D-focused pharmaceutical company that plays exclusively in complex generics — the hard-to-copy molecules that regulators prize and margins reward. Think oncology, specialty pharma, diabetes therapeutics. The kind of stuff that requires actual science, not just a factory and a price tag.
For the last three years, the company’s story was simple: Generic Lenalidomide (Revlimid) launched in March 2022 in the US. It printed money. FY25 saw ~₹750 crore in Revlimid-driven profits. The stock compounded beautifully. Investors slept well.
Then, in Q2 FY26, the patent expired. Revlimid went from hero to zero. Management walked into the quarterly earnings call and said, “We had zero Revlimid this quarter. By the way, we just acquired South Africa’s biggest pharma company, Adcock Ingram, for ₹2,000 crore. We’re also about to launch Semaglutide in India. And we’re hunting for another billion-dollar acquisition. Also, here’s your dividend.”
Markets: “Cool. Up 13% today.”
The shift is deliberate and massive. Natco is transitioning from a single-product (Revlimid) dependent US export story to a multi-geography, multi-product, emerging-markets platform. Adcock Ingram represents 35.75% ownership of a ₹2,464 crore revenue South African pharmaceutical business. Semaglutide is a ₹3+ billion global market opening in India. And the company has 30 Para IV filings sitting in the FDA pipeline waiting to launch.
Concall Highlight (Feb 2026): CEO explicitly stated: “The business has been flat” historically (referring to Adcock); “you’ll probably see real value in the next 18 to 24 months once these registrations start coming.” Translation: This is a 2-year story. Patient capital required.
03 — Business Model: Three Legs. One Fell Off.
The Cash Printer (Now Dead) and the New Bets (Still Running)
Natco operates across five revenue segments. Let’s break them:
Export Formulations (FDF): 44% of Q3 revenue. Complex generics made in India for 50+ countries, especially the US. This is where the money is made. Para IV filings (challenging patents), first-to-file molecules, limited competition. Major customers: Teva, Mylan, Actavis, Alvogen. Revlimid was the crown jewel. Now dead. But the pipeline has 30 Para IV filings, with several expected approvals in the next 12–24 months.
Domestic Formulations: 15% of Q3 revenue (~₹450 crore annualized). Branded products in India targeting oncology, specialty pharma, diabetes, and cardiology. Oncology is their stronghold — early mover advantage in branded cancer drugs. Management target: domestic business should grow >20% this year because of Semaglutide launch (expected March 2026).
APIs: 10% of Q3 revenue. Manufacturing active pharmaceutical ingredients for internal use and external sales. Backward integration provides cost advantage and supply security for complex molecules.
Contract Manufacturing: 29% of Q3 revenue (marked as “Other”). A high-margin service business. Natco manufactures finished dosages for 40+ Indian pharma companies — tablets, capsules, injectables across oncology, antivirals, cardiology. Low R&D burden, stable margins, recurring customers.
Crop Health Sciences: 2% of revenue. Insecticides, fungicides, agrochemicals. Growing but immaterial.
ROCE32.8%Complex Generics Premium
R&D Spend9.1%FY25 of Sales
FDA Plants4Fully Regulated
Para IV Pipeline30Filings Pending
Revlimid Autopsy: In FY25, Revlimid drove ~₹1,100+ crore in revenues. Q4 FY25 saw ₹280+ crore from this single molecule. Q3 FY26: ₹0. The patent expiry in Q2 was both predictable and catastrophic. Management had two years’ notice (patent filed 2020, typical pharma timelines). They used it wisely: Adcock acquisition (announced July, closed November), Semaglutide groundwork, EM expansion. But near-term margins will take a hit. Strategic execution? Yes. Near-term profit pain? Also yes.
04 — Financials Overview
Q3 FY26: The Post-Revlimid Reality
Result type: Quarterly Results | Q3 FY26 EPS: ₹8.46 | Annualised EPS (Q3×4): ₹33.84 | Full-year FY25 EPS: ₹105.26
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 705 | 651 | 1,363 | +8.3% | -48.3% |
| Operating Profit (EBITDA) | 217 | 265 | 571 | -18.2% | -62.0% |
| EBITDA Margin % | 30.7% | 40.7% | 41.9% | -1000 bps | +1120 bps* |
| PAT | 151 | 133 | 518 | +13.9% | -70.9% |
| EPS (₹) | 8.46 | 7.43 | 28.94 | +13.9% | -70.8% |
The Revlimid Cliff vs Base Business Stability: Q2 FY26 revenue was inflated (₹1,363 cr) because it captured Revlimid sell-off before patent expiry. Q3 FY26, stripped of Revlimid, shows the underlying business: ₹705 crore, +8.3% YoY. EBITDA margin contracted to 30.7% (vs 40.7% in Q3 FY25) due to Revlimid’s 50%+ margins being absent, plus elevated R&D spend and one-time amortization from Adcock (~₹18.75 crore write-down for Nov–Dec). Strip those, and normalized EBITDA margin is closer to 35–37%. Management guided Q4 PAT at ₹150 crore (vs ₹271 crore in Q4 FY25), explicitly stating it “doesn’t assume much from Revlimid.”
05 — Valuation: Fair Value Range
Pricing a Pharma Company in a Transition Fog
Join 10,000+ investors who read this every week.
